Phase 3 – Page 2

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

6 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.

Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

7 months ago talkbio0Tagged Antibodies, Clinical Trials, IGF1R protein, human, Phase 3, THRIVE-2, Thyroid associated opthalmopathies, Veligrotug, Viridian

Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

7 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Compass Pathways Delays Phase 3 Psilocybin Trials, Cuts 30% of Workforce to Conserve Cash

8 months ago talkbio0Tagged Cash, Compass Pathways, Conservation, Phase 3, psilocybin trials, psychedelic drug development

Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

9 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical Trials, financing characteristics, Inventiva, lanifibranor, MASH, metabolic dysfunction-associated steatohepatitis, Phase 3

Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

9 months ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition

Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results

10 months ago talkbio0Tagged boehringer ingelheim, Idiopathic Pulmonary Fibrosis, NDA, nerandomilast, Phase 3, Pulmonary Fibrosis

Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)

Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

10 months ago talkbio0Tagged Antibodies, biopharmaceutical development, Clinical Trials, Phase 3, Success, Thrive, Thyroid associated opthalmopathies, Veligrotug, VRDN-001

Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development

Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568

11 months ago talkbio0Tagged Biosciences, Muscarinic Agents, NBI-1117568, Neurocrine, Phase 2, Phase 3, Schizophrenia

Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist